US Centers for Disease Control and Prevention, Pretoria, South Africa.
Howard University Global Initiative, Pretoria, South Africa.
AIDS Behav. 2019 Feb;23(2):375-385. doi: 10.1007/s10461-018-2222-2.
Despite a decade of advancing HIV/AIDS treatment policy in South Africa, 20% of people living with HIV (PLHIV) eligible for antiretroviral treatment (ART) remain untreated. To inform universal test and treat (UTT) implementation in South Africa, this analysis describes the rate, timeliness and determinants of ART initiation among newly diagnosed PLHIV. This analysis used routine data from 35 purposively selected primary clinics in three high HIV-burden districts of South Africa from June 1, 2014 to March 31, 2015. Kaplan-Meier survival curves estimated the rate of ART initiation. We identified predictors of ART initiation rate and timely initiation (within 14 days of eligibility determination) using Cox proportional hazards and multivariable logistic regression models in Stata 14.1. Based on national guidelines, 6826 patients were eligible for ART initiation. Under half of men and non-pregnant women were initiated on ART within 14 days (men: 39.7.0%, 95% CI 37.7-41.9; women: 39.9%, 95% CI 38.1-41.7). Pregnant women initiated at a faster rate (within 14 days: 87.6%, 86.1-89.0). ART initiation and timeliness varied significantly by district, facility location, and age, with little to no variation by World Health Organization stage, or CD4 count. Men and non-pregnant women newly diagnosed with HIV who are eligible for ART in South Africa show suboptimal timeliness of ART initiation. If treatment initiation performance is not improved, UTT implementation will be challenging among men and non-pregnant women. UTT programming should be tailored to district and location categories to address contextual differences influencing treatment initiation.
尽管南非在推进艾滋病病毒/艾滋病治疗政策方面已取得十年进展,但仍有 20%符合抗逆转录病毒治疗 (ART) 条件的艾滋病毒感染者未接受治疗。为了为南非实施普遍检测和治疗 (UTT) 提供信息,本分析描述了新诊断出的艾滋病毒感染者接受抗逆转录病毒治疗的速度、及时性和决定因素。本分析使用了 2014 年 6 月 1 日至 2015 年 3 月 31 日期间,从南非三个艾滋病毒负担高的地区的 35 个指定的初级诊所收集的常规数据。卡普兰-迈耶生存曲线估计了开始接受抗逆转录病毒治疗的速度。我们使用 Cox 比例风险和多变量逻辑回归模型,在 Stata 14.1 中确定了抗逆转录病毒治疗开始率和及时开始(在符合资格确定后 14 天内)的预测因素。根据国家指南,有 6826 名患者有资格开始接受抗逆转录病毒治疗。不到一半的男性和非孕妇在 14 天内开始接受抗逆转录病毒治疗(男性:39.7.0%,95%CI 37.7-41.9;女性:39.9%,95%CI 38.1-41.7)。孕妇的启动速度更快(在 14 天内:87.6%,86.1-89.0)。抗逆转录病毒治疗的开始和及时性在不同地区、医疗机构位置和年龄之间有显著差异,而与世界卫生组织分期或 CD4 计数差异不大。在南非,新诊断出的符合接受抗逆转录病毒治疗条件的艾滋病毒男性和非孕妇,抗逆转录病毒治疗的开始时间并不理想。如果不提高治疗开始的速度,那么男性和非孕妇实施普遍检测和治疗将会具有挑战性。普遍检测和治疗方案应根据地区和地点类别进行调整,以解决影响治疗启动的背景差异。